Finance

Lists
CRBP:NASDAQ
Corbus Pharmaceuticals Holdings Inc
$10.49
+3.96%
(+0.40) 1D
$10.50
+0.10% (+0.010)
Pre-market
Closed: Aug 17, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CRBP...
Open
$10.06
High
$10.58
Low
$10.05
Mkt. cap
202.89M
Avg. vol.
308.80K
Volume
0.00
52-wk high
$20.56
52-wk low
$7.12
EPS
-$6.17
Beta
2.59
Shares outstanding
19.34M
No. of employees
36
Open
$10.06
High
$10.58
Low
$10.05
Mkt. cap
202.89M
Avg. vol.
308.80K
Volume
0.00
52-wk high
$20.56
52-wk low
$7.12
EPS
-$6.17
Beta
2.59
Shares outstanding
19.34M
No. of employees
36
News stories
From web sources and news partners
About Corbus Pharmaceuticals Holdings Inc
CEO-
Employees36
FoundedJan 1, 2009
Headquarters-
SectorBiotechnology
Websitecorbuspharma.com
Analyst ratings
Based on 8 analysts giving stock ratings to CRBP in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for CRBP in the last 3 months.
Highest
Current $10.49
$48.00 (+357.58%)
Average
$37.86 (+260.92%)
Lowest
$30.00 (+185.99%)
Analyst
Recommendation
Action
Price target
Projected
Date
Graig Suvannavejh
Mizuho Securities
Buy
Maintained
$33.00
+214.6%
08/12/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$36.00
+243.2%
08/12/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
$38.00
+262.2%
08/07/2026
Jeff Jones
Oppenheimer
Buy
Reiterated
$48.00
+357.6%
08/07/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$48.00
+357.6%
08/07/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$35.00
+233.7%
08/07/2026
Andy Hsieh
William Blair
Buy
Reiterated
-
-
08/06/2026
Paul Jeng
Guggenheim
Buy
Maintained
$45.00
+329%
06/02/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$30.00
+186%
05/27/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$38.00
+262.2%
05/13/2026
Maury Raycroft
Jefferies
Buy
Maintained
$33.00
+214.6%
05/12/2026
Unknown Analyst
B. Riley Securities
Buy
Reiterated
$28.00
+166.9%
04/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
20.86M
18.41M
19.82M
31.18M
Cost of revenue
20.86M
18.41M
19.82M
31.18M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.56M
3.56M
4.48M
5.02M
Operating expense
3.56M
3.56M
4.48M
5.02M
Total operating expenses
24.42M
21.97M
24.30M
36.19M
Operating income
-24.42M
-21.97M
-24.30M
-36.19M
Other non operating income
-50.00K
-1.10M
-67.00K
-11.00K
EBT including unusual items
-23.34M
-20.56M
-22.97M
-35.04M
EBT excluding unusual items
-23.34M
-21.66M
-22.97M
-35.04M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-23.34M
-20.56M
-22.97M
-35.04M
Net profit margin
-
-
-
-
Earnings per share
-1.90
-1.25
-1.23
-1.81
Interest and investment income
1.12M
1.41M
1.40M
1.16M
Interest expense
-
-
-
-
Net interest expenses
1.12M
1.41M
1.40M
1.16M
Depreciation and amortization charges
-
-
-
-
EBITDA
-24.37M
-21.92M
-24.26M
-36.14M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps